This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-06. Anything still debated is marked as such rather than presented as settled.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
=== Dogs === Dogs have been used to diagnose symptomatic and asymptomatic individuals with metabolic and infectious diseases because of their highly sensitive olfaction due to a higher neuron packing density and threefold the number of functional genes encoding olfactory receptors relative to humans. This increase in receptors results in dogs possessing a 10,000 to 100,000 times higher accuracy in specially recognizing chemical messengers than humans. They have been frequently used to diagnose asymptomatic individuals with various infectious diseases such as SARS CoV-2, H1N1 Influenza, malaria, bovine virus infection, etc.
=== Carbon footprint === UPS reported Total CO2e emissions (Direct + Indirect) for the twelve months ending December 31, 2020, at 16,500 Kt (+1,546/+10% y-o-y). UPS aims to reach net zero emissions by 2050.
=== Antimicrobial agents === Rhizopus cultures responsible for the fermentation of tempeh from soybean produce natural, heat-stable antimicrobial agents against spoilage and disease-causing microorganisms, extending the shelf life of the fermented product through microbial antagonism. The mold is capable of inhibiting the growth of other fungi such as Aspergillus flavus and Aspergillus parasiticus by interfering with the accumulation of aflatoxin (especially aflatoxin B1), the mycotoxin of greatest concern. R. oligosporus has also been reported to produce four to five antibacterial substances during fermentation process. It produces phenolic compounds against pathogenic bacteria such as Helicobacter pylori and an antibacterial protein has been identified with activities against Bacillus species (especially against Bacillus subtilis and Bacillus cereus), Staphylococcus aureus, and Streptococcus cremoris.
Sources: en.wikipedia.org
When an allergen (pollen, dust) enters the body, the body produces immunoglobulin E antibodies, resulting in an antigen-antibody reaction. The antibodies are attached to mast cells, which release bioactive substances such as histamine and serotonin. Histamine causes expansion of blood vessels, resulting in allergic reactions such as low blood pressure, increased heart rate, skin itchiness, sneezing, runny nose, etc. Narirutin is said to prevent the release of histamine by the mast cells, reducing the allergic symptoms.
Micropore: With a Slit width less than 2 nm, they are usually found at the end of larger pores and their main characteristic is to have superimposed wall potentials. This means, the particles inside them feel attracted towards their solid walls so they make contact with the active sites. Mesopore: With a Slit width between 2 and 50 nm these mid-size pores have the main objective to withhold capillary condensation and is usually found before the micropores. Macropore: With a Slit width bigger than 50 nm, these are the biggest size pores with the main purpose of being the main path for the molecules to enter the particle and later on redistribute through the other smaller channels
Lack of sufficient insulin (but enough to prevent ketosis) Poor kidney function Poor fluid intake (dehydration) Older age (50–70 years) Certain medical conditions (cerebral vascular injury, myocardial infarction, sepsis) Certain medications (glucocorticoids, beta-blockers, thiazide diuretics, calcium channel blockers, and phenytoin)
Sources: en.wikipedia.org
Even though the original relation was based on studies of spruce, Hankinson's equation has been found to be remarkably accurate for many other types of wood. A generalized form of the Hankinson formula has also been used for predicting the uniaxial tensile strength of wood at an angle to the grain. This formula has the form
== Uses == The useful physiological properties of yeast have led to their use in the field of biotechnology. Fermentation of sugars by yeast is the oldest and largest application of this technology. Many types of yeasts are used for making many foods: baker's yeast in bread production, brewer's yeast in beer fermentation, and yeast in wine fermentation and for xylitol production. So-called red rice yeast is actually a mold, Monascus purpureus. Yeasts include some of the most widely used model organisms for genetics and cell biology.
== Controversies == Questions about certain areas of forensic science, such as fingerprint evidence and the assumptions behind these disciplines have been brought to light in some publications including the New York Post. The article stated that "No one has proved even the basic assumption: That everyone's fingerprint is unique." The article also stated that "Now such assumptions are being questioned—and with it may come a radical change in how forensic science is used by police departments and prosecutors." Law professor Jessica Gabel said on NOVA that forensic science "lacks the rigors, the standards, the quality controls and procedures that we find, usually, in science". The National Institute of Standards and Technology has reviewed the scientific foundations of bite-mark analysis used in forensic science. Bite mark analysis is a forensic science technique that analyzes the marks on the victim's skin compared to the suspects teeth. NIST reviewed the findings of the National Academies of Sciences, Engineering, and Medicine 2009 study. The National Academics of Sciences, Engineering, and Medicine conducted research to address the issues of reliability, accuracy, and reliability of bitemark analysis, where they concluded that there is a lack of sufficient scientific foundation to support the data. Yet the technique is still legal to use in court as evidence. NIST funded a 2019 meeting that consisted of dentists, lawyers, researchers and others to address the gaps in this field. In the US, on 25 June 2009, the Supreme Court issued a 5-to-4 decision in Melendez-Diaz v.
As part of the discovery phase, Valve received a number of documents in Korean, which a new intern at Valve was able to translate, purporting that Vivendi had directed the destruction of evidence for the case. When shown to the court, the judge took action to block Vivendi's countersuits, turning the case in Valve's direction. On November 29, 2004, Judge Thomas Samuel Zilly of the U.S. District Court for the Western District of Washington ruled in favor of Valve. The ruling stated that Vivendi Universal and its affiliates (including Sierra) were not authorized to distribute Valve games, either directly or indirectly, through cyber cafés to end users for pay-to-play activities pursuant to the parties' publishing agreement. In addition, Judge Zilly ruled that Valve could recover copyright damages for infringements without regard to the publishing agreement's limitation of liability clause. Valve posted on the Steam website that the companies had come to a settlement in court on April 29, 2005. As a result of the trial, the arbitrator also awarded Valve $2,391,932.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.